DSS Withdraws Form S-1 Registration, Plans New Financing and Impact Biomedical Merger
DSS•DSS, Inc. has withdrawn its Form S-1 registration with the SEC after finding market conditions and deal terms inadequate to reflect its value. The company says it can access capital markets on more favorable terms and will continue evaluating financing alternatives and its planned Impact Biomedical merger.
1. Registration Withdrawal
DSS, Inc. withdrew its previously filed Form S-1 registration with the SEC after management and the Board concluded that current market conditions and deal terms did not reflect the value the company has built for shareholders.
2. Capital Markets Strategy
The company stated it remains well-positioned to access capital markets and will only pursue offerings when they align with its strategic plan and secure the most favorable terms to support long-term growth.
3. Impact Biomedical Merger
DSS continues advancing its announced merger with Impact Biomedical, viewing it as a key strategic initiative likely to create meaningful long-term value by leveraging DSS's biotechnology and product packaging expertise.
